OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
Objective: Lung cancer Pemetrexed is novel multitargeted antifolate which inhibits three key enzymes in the folate metabolic pathwaw. Methods: From May 2010 to March 2012 twenty two consecutive patients with morphologically proven advanced non- squamous non- small cell lung cancer entered the study....
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Peytchinski Publishing,
2013-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |